Open access simulation toolbox for the grid connection of offshore wind farms using multi-terminal HVDC networks

Decarbonisation of the European electricity system can become dauntingly costly due to transmission and distribution network issues arising from the integration of intermittent renewable generation sources. It is expected that wind energy will be the principal renewable source by 2050 and, as such, a number of initiatives in the academia and in the industry are being carried out to propose solutions to best accommodate the wind resource. This paper presents work carried out by DEMO 1 partners within the EU FP7 project BEST PATHS. A MATLAB/Simulink toolbox consisting of the necessary building blocks for the simulation and integration of offshore wind farms using enabling technologies such as multiterminal high-voltage direct-current grids is presented. To illustrate the toolbox capabilities, a number of system topologies is studied. System performance is assessed and measured against a set of key performance indicators. To ensure knowledge dissemination, the toolbox has been made available as open access in the BEST PATHS project website

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma

Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontline setting. Real-life clinical data of cabozantinib for HCC are still lacking. Moreover, the prognostic factors for HCC treated with cabozantinib have not been investigated. Methods: We evaluated clinical data and outcome of HCC patients who received cabozantinib in the legal context of named patient use in Italy. Results: Ninety-six patients from 15 centres received cabozantinib. All patients had preserved liver function (Child-Pugh A), mostly with an advanced HCC (77.1%) in a third-line setting (75.0%). The prevalence of performance status (PS) > 0, macrovascular invasion (MVI), extrahepatic spread, and alpha-fetoprotein (AFP) >400 ng/mL was 50.0, 30.2, 67.7, and 44.8%, respectively. Median overall survival (OS) and progression-free survival were 12.1 (95% confidence interval 9.4-14.8) and 5.1 (3.3-6.9) months, respectively. Most common treatment-related adverse events (AEs) were fatigue (67.7%), diarrhoea (54.2%), anorexia (45.8%), HFSR (43.8%), weight loss (24.0%), and hypertension (24.0%). Most common treatment-related Grade 3-4 AEs were fatigue (6.3%), HFSR (6.3%), and increased aminotransferases (6.3%). MVI, ECOG-PS > 0, and AFP >400 ng/mL predicted a worse OS. Discontinuation for intolerance and no new extrahepatic lesions at the progression were associated with better outcomes. Conclusions: In a real-life Western scenario (mostly in a third-line setting), cabozantinib efficacy and safety data were comparable with those reported in its registration trial. Data regarding the prognostic factors might help in patient selection and design of clinical trials

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

BACKGROUND: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis. Patients who had systemic sclerosis with an onset of the first non-Raynaud's symptom within the past 7 years and a high-resolution computed tomographic scan that showed fibrosis affecting at least 10% of the lungs were randomly assigned, in a 1:1 ratio, to receive 150 mg of nintedanib, administered orally twice daily, or placebo. The primary end point was the annual rate of decline in forced vital capacity (FVC), assessed over a 52-week period. Key secondary end points were absolute changes from baseline in the modified Rodnan skin score and in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 52. RESULTS: A total of 576 patients received at least one dose of nintedanib or placebo; 51.9% had diffuse cutaneous systemic sclerosis, and 48.4% were receiving mycophenolate at baseline. In the primary end-point analysis, the adjusted annual rate of change in FVC was 1252.4 ml per year in the nintedanib group and 1293.3 ml per year in the placebo group (difference, 41.0 ml per year; 95% confidence interval [CI], 2.9 to 79.0; P=0.04). Sensitivity analyses based on multiple imputation for missing data yielded P values for the primary end point ranging from 0.06 to 0.10. The change from baseline in the modified Rodnan skin score and the total score on the SGRQ at week 52 did not differ significantly between the trial groups, with differences of 120.21 (95% CI, 120.94 to 0.53; P=0.58) and 1.69 (95% CI, 120.73 to 4.12 [not adjusted for multiple comparisons]), respectively. Diarrhea, the most common adverse event, was reported in 75.7% of the patients in the nintedanib group and in 31.6% of those in the placebo group. CONCLUSIONS: Among patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis. The adverse-event profile of nintedanib observed in this trial was similar to that observed in patients with idiopathic pulmonary fibrosis; gastrointestinal adverse events, including diarrhea, were more common with nintedanib than with placebo

) Maceil, C. E.; In The Encyclopedia of Nuclear Magnetic Resonance

Evanescent-wave cavity ring-down spectroscopy has been applied to a planar fused-silica surface covered with crystal violet (CV + ) cations to characterize the silanol groups indirectly. A radiation-polarization dependence of the adsorption isotherm of CV + at the CH 3 CN/silica interface is measured and fit to a two-site Langmuir equation to determine the relative populations of two different types of isolated silanol groups. CV + binding at type I sites yields a free energy of adsorption of -29.9 ( 0.2 kJ/mol and a saturation surface density of (7.4 ( 0.5) × 10 12 cm -2 , whereas the values of -17.9 ( 0.4 kJ/mol and (3.1 ( 0.4) × 10 13 cm -2 are obtained for the type II sites. The CV + cations, each with a planar area of ∼120 Å 2 , seem to be aligned randomly while lying over the SiOtype I sites, thereby suggesting that this type of site may be surrounded by a large empty surface area (>480 Å 2 ). In contrast, the CV + cations on a type II sites are restricted with an average angle of ∼40°tilted off the surface normal, suggesting that the CV + cations on these sites are grouped closely together. The average tilt angle increases with increasing concentration of crystal violet so that CV + cations may be separated from each other to minimize the repulsion of nearby CV + and SiOH sites. Adsorption behavior of organic molecules on silica surfaces has been the major theme of interface studies for improving the efficiency of chromatographic separations. When cationic molecules are involved, the strong electrostatic interaction with the negatively charged silanol (SiOH) groups on the surface of the stationary-phase silica may cause unwanted peak broadening and tailing, mainly from a slow kinetic response of the electrostatic adsorption. [1][2][3][4][5][6] The surface charge density is one of the primary factors influencing the strength of electrostatics. Accordingly, insight into how the cationic molecules interact with the local silanol groups of the silica surface should aid in the improvement of the design of surface modifications. Silanol groups play the main role in influencing the interfacial adsorption behavior, possessing an average surface density of ∼4.9 × 10 14 cm -2 on the silica surface 7-9 or an average surface area of 20.4 Å 2 per silanol group. As compared to silica sol particles, which have higher surface areas of (0.1-5) × 10 22 Å 2 /g, 7-9 only a few studies focus on characterization of silanol groups on a planar silica surface. 10-12 Ong et al. 10 first reported that isolated and vicinal silanol groups both exist at the water/silica interface possessing different pK a values of 4.9 and 8.5, with corresponding surface populations of 19 and 81%, respectively. These results were confirmed by means of cross-polarization magic angle spinning NMR 13 and fluorescence microscopy. 14 The isolated silanol groups with pK a ) 4.9 are anticipated to be separated far from each other (>5.5 Å), permitting proton dissociation. The vicinal silanol groups are located so closely as to form hydrogen bonds directly with their neighbors (<3.3 Å), which share 46% of the surface population, or through a water-molecule bridge (3.5-5.5 Å), which covers ∼35% of the surface population. 12,[15][16][17] By using second harmonic generation (SHG) with a cationic crystal violet (CV + ) molecular probe to investigate the local density distribution of the isolated silanols (pK a ) 4.9) on the planar fusedsilica surface, Xu and co-workers 12 classified them into two types. The first type of silanol group is anticipated to be surrounded by a large empty surface area (g120 Å 2 ) with a surface density o

Molecular tracing of SARS-CoV-2 in Italy in the first three months of the epidemic

The aim of this study is the characterization and genomic tracing by phylogenetic analyses of 59 new SARS-CoV-2 Italian isolates obtained from patients attending clinical centres in North and Central Italy until the end of April 2020. All but one of the newly-characterized genomes belonged to the lineage B.1, the most frequently identified in European countries, including Italy. Only a single sequence was found to belong to lineage B. A mean of 6 nucleotide substitutions per viral genome was observed, without significant differences between synonymous and non-synonymous mutations, indicating genetic drift as a major source for virus evolution. tMRCA estimation confirmed the probable origin of the epidemic between the end of January and the beginning of February with a rapid increase in the number of infections between the end of February and mid-March. Since early February, an effective reproduction number (Re) greater than 1 was estimated, which then increased reaching the peak of 2.3 in early March, confirming the circulation of the virus before the first COVID-19 cases were documented. Continuous use of state-of-the-art methods for molecular surveillance is warranted to trace virus circulation and evolution and inform effective prevention and containment of future SARS-CoV-2 outbreaks